title: The effect of droperidol on objective markers of patient cooperation and vital signs during esophagogastroduodenoscopy: a randomized, double-blind, placebo-controlled, prospective investigation.
abstract: We investigated the effect of droperidol on objective markers of cooperation and vital signs in 140 patients undergoing elective diagnostic esophagogastroduodenoscopy. Procedure duration and the total doses of midazolam and meperidine required during the procedure were evaluated as objective markers of patient cooperation. The droperidol group comprised 66 patients and the placebo group 74 patients. Patient and procedure characteristics were similar for both groups. Droperidol produced a 10% reduction in procedure duration. Linear multiple regression modeling revealed droperidol to be a significant predictor of procedure duration (p = .036). Droperidol significantly reduced midazolam and meperidine requirements (p < .01). Nonetheless, four patients in the droperidol group received naloxone to reverse prolonged, excessive drowsiness. Droperidol produced a significant reduction in procedure-associated increase in pulse rate but did not exacerbate procedure-associated reduction in mean arterial pressure. Droperidol favorably influences markers of patient cooperation during elective, diagnostic esophagogastroduodenoscopy. However, the clinical significance of these changes is unclear.
authors.affiliation: University of Missouri School of Medicine, Department of Internal Medicine, Columbia, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Barthel
authors.forename: J B
authors.initials: JB
authors.lastname: Marshall
authors.forename: P D
authors.initials: PD
authors.lastname: King
authors.forename: S A
authors.initials: SA
authors.lastname: Afridi
authors.forename: L G
authors.initials: LG
authors.lastname: Gibb
authors.forename: R
authors.initials: R
authors.lastname: Madsen
mesh_terms: D000759:Adjuvants, Anesthesia; D014150:Antipsychotic Agents; D016292:Procedural Sedation; D004311:Double-Blind Method; D004329:Droperidol; D016145:Endoscopy, Digestive System; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D016014:Linear Models; D008297:Male; D008614:Meperidine / Q000008:administration & dosage; D008874:Midazolam / Q000008:administration & dosage; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010349:Patient Compliance; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D000759:Adjuvants, Anesthesia; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D008614:Meperidine; D004329:Droperidol; D008874:Midazolam